Veppanu-Vepdegestrant
Veppanu (vepdegestrant) is a new oral targeted therapy approved for the treatment of adults with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer or metastatic breast cancer after progression on prior endocrine therapy. Veppanu is a first-in-class PROTAC estrogen receptor degrader that selectively degrades the estrogen receptor, a critical driver of tumor growth and endocrine resistance in […]
Beqalzi-Sonrotoclax
Beqalzi (sonrotoclax) is an oral BCL-2 inhibitor indicated to treat adult patients with relapsed or refractory mantle cell lymphoma (MCL) who have received prior therapies, including a BTK inhibitor. Beqalzi targets the BCL-2 protein, which prevents cells from dying in a programmed fashion, and helps control disease progression in patients with advanced hematologic malignancies. Beqalzi […]
Baxfendy-Baxdrostat
Baxfendy (baxdrostat) is a first-in-class oral therapy approved for adults with uncontrolled hypertension and resistant high blood pressure. The drug selectively inhibits aldosterone synthase, reducing excess aldosterone production, a key factor associated with persistent hypertension and increased cardiovascular risk. By targeting a hormonal pathway often overlooked by conventional blood pressure medications, Baxfendy introduces a new […]
Hepcludex-Bulevirtide-Gmod
Hepcludex (bulevirtide) is the first approved therapy with an indication specifically for chronic hepatitis D virus (HDV) infection, a severe form of viral hepatitis seen in patients co-infected with hepatitis B virus (HBV). The drug prevents the virus from entering liver cells, which helps prevent further infection and damage to the liver. Hepcludex is a […]
Decnupaz-Pivekimab-Sunirine-Pvzy
Decnupaz (pivekimab sunirine-pvzy) is a CD123-directed antibody-drug conjugate (ADC) developed for the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN), a rare and aggressive hematologic cancer. The therapy delivers a potent cytotoxic payload directly to cancer cells that express CD123, helping to maximize antitumor activity while minimizing damage to healthy tissues. Decnupaz, as a targeted […]
Zaynich-Cefepime-And-Zidebactam
Zaynich (cefepime-zidebactam) is a novel antibacterial therapy for complicated urinary tract infections (cUTI) and serious infections caused by multidrug-resistant Gram-negative bacteria. The cefepime/zidebactam combination is designed to overcome resistance mechanisms and restore antibiotic activity against difficult-to-treat pathogens. Antimicrobial resistance remains a challenge to healthcare systems globally, and Zaynich offers an important new option for the […]
Xocova-Ensitrelvir
Xocova (ensitrelvir) is an oral antiviral indicated for the prevention and treatment of COVID-19 due to SARS-CoV-2 infection. Xocova selectively inhibits the 3CL protease, blocking this essential viral enzyme required for replication, helping to reduce viral load and limit disease progression. This therapy is a significant advance in the treatment of COVID-19 with an easy-to-take […]
Idvynso-Doravirine And Islatravir
Idvynso is a prescription oral therapy indicated as a complete regimen for the treatment of HIV-1 infection in adults who are already virologically suppressed on a stable antiretroviral regimen. Designed to replace an existing treatment in patients with no history of virologic failure and no known resistance to Doravirine, a next-generation non-nucleoside reverse transcriptase inhibitor […]
Foundayo-Orforglipron
Foundayo is an oral, once-daily, investigational GLP-1 receptor pathway targeting therapy for chronic weight management in adults with obesity. Unlike injectable GLP-1 receptor agonists, orforglipron is a small-molecule, non-peptide option designed for convenient administration without food or water restrictions. Its mechanism focuses on appetite regulation, increased satiety, and reduced caloric intake, addressing key biological drivers […]
Awiqli-Insulin Icodec-Abae
Awiqli (Insulin Icodec-Abae) is a next-generation, ultra-long-acting basal insulin developed by Novo Nordisk for the treatment of adults with Type 2 Diabetes Mellitus. Designed for once-weekly administration, insulin icodec-abæ forms a stable subcutaneous depot and binds reversibly to albumin, enabling slow, continuous insulin release over an extended period. This unique pharmacokinetic profile helps maintain consistent […]
